Respiratory medicine · 2024
Effect of continuous positive airway pressure on cardiometabolic risk factors in patients with obstructive sleep apnea: A systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lv Mengjiao, Mao Jing, Wang Saikun, Zhang Changyue, Qian Chunting, Zhu Ruiting, Xiong Sikun, Zhang Yong, Guo Lirong
Аннотация
OBJECTIVE: Cardiometabolic risk factors (CMRFs) play a crucial role in the occurrence and development of cardiovascular diseases. Obstructive sleep apnea (OSA) causes abnormalities of CMRFs. Continuous positive airway pressure (CPAP) is a widely used treatment for OSA. This systematic review and meta-analysis aimed to investigate the effect of CPAP on CMRFs in patients with OSA.
METHODS: A search of PubMed, Cochrane Library, Scopus, Web of Science, and Embase was conducted to find randomized controlled trials up to December 3, 2023. The quality of the studies included was evaluated using the Cochrane Bias Risk Tool 2.0, and a meta-analysis was carried out using Stata15.1 software. The effect sizes for this meta-analysis were represented as the weighted mean difference (WMD) and 95 % confidence interval (CI).
RESULTS: A total of 52 studies with 10,104 participants were analyzed. The results showed that CPAP significantly lowered systolic blood pressure (WMD: -2.04 mmHg; 95%CI: -3.56 to -0.51), diastolic blood pressure (WMD: -1.40 mmHg; 95%CI: -2.36 to -0.44), total cholesterol (WMD: -0.27 mmol/L; 95%CI: -0.51 to -0.04), triglycerides (WMD: -0.02 mmol/L; 95%CI: -0.03 to -0.01), and fasting blood glucose (WMD: -0.15 mmol/L; 95%CI: -0.16 to -0.13) in patients with OSA. However, there was no significant change in low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, waist circumference, or body mass index after CPAP.
CONCLUSION: In summary, this meta-analysis demonstrated that CPAP effectively reduced certain CMRFs in patients with OSA, offering new insights for cardiovascular disease prevention.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO, identifier CRD42023456380.
METHODS: A search of PubMed, Cochrane Library, Scopus, Web of Science, and Embase was conducted to find randomized controlled trials up to December 3, 2023. The quality of the studies included was evaluated using the Cochrane Bias Risk Tool 2.0, and a meta-analysis was carried out using Stata15.1 software. The effect sizes for this meta-analysis were represented as the weighted mean difference (WMD) and 95 % confidence interval (CI).
RESULTS: A total of 52 studies with 10,104 participants were analyzed. The results showed that CPAP significantly lowered systolic blood pressure (WMD: -2.04 mmHg; 95%CI: -3.56 to -0.51), diastolic blood pressure (WMD: -1.40 mmHg; 95%CI: -2.36 to -0.44), total cholesterol (WMD: -0.27 mmol/L; 95%CI: -0.51 to -0.04), triglycerides (WMD: -0.02 mmol/L; 95%CI: -0.03 to -0.01), and fasting blood glucose (WMD: -0.15 mmol/L; 95%CI: -0.16 to -0.13) in patients with OSA. However, there was no significant change in low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, waist circumference, or body mass index after CPAP.
CONCLUSION: In summary, this meta-analysis demonstrated that CPAP effectively reduced certain CMRFs in patients with OSA, offering new insights for cardiovascular disease prevention.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO, identifier CRD42023456380.